Sumitomo Mitsui Trust Group Inc. Has $143.91 Million Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

Sumitomo Mitsui Trust Group Inc. lifted its position in 10x Genomics, Inc. (NASDAQ:TXG) by 3.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,373,212 shares of the company’s stock after purchasing an additional 230,145 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 5.29% of 10x Genomics worth $143,907,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC lifted its stake in 10x Genomics by 113.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 698 shares of the company’s stock worth $26,000 after purchasing an additional 371 shares during the period. GAMMA Investing LLC lifted its position in shares of 10x Genomics by 451.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock worth $35,000 after buying an additional 1,265 shares during the period. Capital Performance Advisors LLP acquired a new stake in 10x Genomics in the 3rd quarter valued at $35,000. First Horizon Advisors Inc. boosted its stake in 10x Genomics by 74.1% in the 2nd quarter. First Horizon Advisors Inc. now owns 1,898 shares of the company’s stock valued at $37,000 after buying an additional 808 shares in the last quarter. Finally, Covestor Ltd grew its position in 10x Genomics by 501.7% in the first quarter. Covestor Ltd now owns 1,047 shares of the company’s stock valued at $39,000 after acquiring an additional 873 shares during the period. 84.68% of the stock is owned by institutional investors.

10x Genomics Trading Down 1.4 %

Shares of 10x Genomics stock opened at $15.68 on Wednesday. 10x Genomics, Inc. has a 52 week low of $14.02 and a 52 week high of $57.90. The firm has a fifty day moving average of $19.07 and a two-hundred day moving average of $20.73.

10x Genomics (NASDAQ:TXG) last released its earnings results on Tuesday, October 29th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.04. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The firm had revenue of $151.65 million for the quarter, compared to analyst estimates of $158.84 million. During the same quarter in the prior year, the firm posted ($0.51) earnings per share. The company’s quarterly revenue was down 1.3% on a year-over-year basis. Sell-side analysts predict that 10x Genomics, Inc. will post -1.4 earnings per share for the current year.

Insider Activity at 10x Genomics

In related news, insider Benjamin J. Hindson sold 4,351 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total transaction of $98,028.03. Following the completion of the transaction, the insider now owns 345,704 shares in the company, valued at approximately $7,788,711.12. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Serge Saxonov sold 6,749 shares of 10x Genomics stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total transaction of $152,054.97. Following the transaction, the chief executive officer now owns 882,467 shares in the company, valued at $19,881,981.51. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Benjamin J. Hindson sold 4,351 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total value of $98,028.03. Following the completion of the transaction, the insider now owns 345,704 shares of the company’s stock, valued at $7,788,711.12. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 14,061 shares of company stock worth $316,794 in the last ninety days. Company insiders own 10.03% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on TXG. Citigroup cut their price objective on 10x Genomics from $35.00 to $23.00 and set a “buy” rating for the company in a report on Wednesday, October 30th. Stifel Nicolaus reduced their price target on shares of 10x Genomics from $53.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, July 16th. Barclays dropped their price objective on shares of 10x Genomics from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Friday, November 1st. JPMorgan Chase & Co. reduced their target price on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday, October 30th. Finally, Stephens reaffirmed an “overweight” rating and set a $30.00 price target on shares of 10x Genomics in a report on Thursday, October 10th. One analyst has rated the stock with a sell rating, seven have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $29.19.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.